Details of the Drug Reposition

General Information of This Drug (ID: DMK2L38)

Drug Name
M3814   DMK2L38
Synonyms
MOWXJLUYGFNTAL-DEOSSOPVSA-N; M-3814; 1637542-33-6; M-3814(nedisertib); nedisertib (proposed INN); UNII-GN429E725A; GTPL9766; SCHEMBL16235559; GN429E725A; MSC2490484A; EX-A1679; example 136 [WO2014183850]; HY-101570; CS-0021723; (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Locally advanced rectal cancer DISIEEZM 2B92 Phase 1/2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03770689) Study of Peposertib in Combination With Capecitabine and Radiotherapy in Rectal Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)